| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued.
OraSure Technologies saw a decrease in earnings per share from 0.47 in Q1 to $0.09 now. Zymeworks has reported Q2 earnings per share at $-0.75, which has decreased by 120.59% compared to Q1, which was -0.34. This quarter, Organon experienced an increase in earnings per share, which was $1.11 in Q1 and is now $1.31. Most recently, the company reported a dividend yield of 5.14%, which has increased by 0.52% from last quarter's yield of 4.62%.
Agile Therapeutics has reported Q2 earnings per share at $-3.1, which has increased by 60.05% compared to Q1, which was -7.76. This quarter, Aprea Therapeutics experienced an increase in earnings per share, which was $-1.34 in Q1 and is now $-0.87.
The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.
